Matthew R Smith, MD, PhD
Fizazi K et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). Genitourinary Cancers Symposium 2019;Abstract 140.
Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol 2014;11(6):335-45. Abstract
Hussain M et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465-74. Abstract
Hussain M et al. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). Genitourinary Cancers Symposium 2018;Abstract 3.
Scher HI et al. Prevalence of prostate cancer clinical states and mortality in the United States: Estimates using a dynamic progression model. PLoS One 2015;10(10);e0139440. Abstract
Smith MR et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Eng J Med 2018; 378(15):1408-18. Abstract
Smith MR et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013;31(30):3800-6. Abstract
Smith MR et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23(13):2918-25. Abstract
Zurth C et al. Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography. Genitourinary Cancers Symposium 2019;Abstract 156.
Cora N Sternberg, MD
Armstrong AJ et al. Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. Genitourinary Cancers Symposium 2019;Abstract 687.
Fizazi K et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). Genitourinary Cancers Symposium 2019;Abstract 140.
Fizazi K et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352‒60. Abstract
James ND et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338-51. Abstract
James ND et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024):1163-77. Abstract
Kyriakopoulos CE et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36(11):1080-7. Abstract
Vale CL et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: A systematic review and meta-analyses of aggregate data. Lancet Oncol 2016;17(2):243-56. Abstract
Howard I Scher, MD
Antonarakis ES et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371(11):1028-38. Abstract
Antonarakis ES et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 2015;1(5):582-91. Abstract
Armenia J et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet 2018;50(5):645-51. Abstract
Scher HI et al. Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol 2017;71(6):874-82. Abstract
Scher HI et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34(12):1402-18. Abstract
Sharma P et al. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). Genitourinary Cancers Symposium 2019;Abstract 142.
Watson PA et al. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 2015;15(12):701-11. Abstract
Yu EY et al. Keynote-365 Cohort A: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2019;Abstract 145.
Emmanuel S Antonarakis, MD
Bryant HE et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005(7035);434:913-7. Abstract
Carney B et al. Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nat Commun 2018;9(1):176. Abstract
Clarke N et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2018;19(7):975-86. Abstract
Farmer H et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005(7035);434:917-21. Abstract
Fraser M et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 2017;541(7637):359-64. Abstract
Handy Marshall C et al. Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations. Genitourinary Cancers Symposium 2019;Abstract 154.
Isaacsson Velho P et al. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 2018;78(5):401-7. Abstract
Mateo J et al. DNA-Repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373(18):1697-708. Abstract
Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. Abstract
Pritchard CC et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375(5):443-53. Abstract
Robinson D et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215-28. Abstract
Schweizer MT et al. Genomic characterization of ductal adenocarcinoma of the prostate. Proc ASCO 2018;Abstract 5030.
A Oliver Sartor, MD
Hofman MS et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19(6):825-33. Abstract
Hofman MS et al. Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA. Proc ESMO 2017;Abstract 785O.
O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015;60(4):547-60. Abstract
Smith MR et al. ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Proc ESMO 2018;Abstract LBA30.